Celgene Corporation's Revlimid Side Effects Linked to Protein in Study

An early-stage trial of Celgene Corp's (CELG.O) multiple myeloma drug Revlimid has found that it interacts with another protein that affect its dose levels in the body as well as potential side affects, according to researchers. Revlimid, also known as lenalidomide, was approved by the U.S. Food and Drug Administration in 2005 for treating myelodysplasia syndromes and in 2006 for multiple myeloma. Celgene is also seeking to win approval of the drug as a maintenance therapy following a stem cell transplant. Researchers at the Ohio State University Comprehensive Cancer Center found that lenalidomide interacts with P-glycoprotein (Pgp), a molecule that pumps potentially toxic chemicals out of cells and aids in removing them from the body.

Back to news